BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

In order to provide sufficient time for additional investors to participate in the Private Placement, the Company has extended the closing date of its fourth and final tranche (the "Final Tranche") of the Private Placement previously scheduled for January 24, 2025, to on or about, but no later than, February 7, 2025. The Company intends to use the net proceeds of the Final Tranche for working capital. All securities to be issued pursuant to the Final Tranche will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities law.

UNITED STATES, 24/01/2025 (informazione.news - comunicati stampa - salute e benessere)

In order to provide sufficient time for additional investors to participate in the Private Placement, the Company has extended the closing date of its fourth and final tranche (the " ") of the Private Placement previously scheduled for January 24, 2025 , to on or about, but no later than, February 7, 2025 . The Company intends to use the net proceeds of the Final Tranche for working capital. All securities to be issued pursuant to the Final Tranche will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities described herein have not been, and will not be, registered under the , as amended (the " "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom.

BioVaxys Technology Corp. (www.biovaxys.com), a company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys' common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

Signed " "
James Passin , Chief Executive Officer
Phone: +1 740 358 0555

Logo - https://mma.prnewswire.com/media/2415135/5132506/BioVaxys_Technology_Corp_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-announces-extension-of-private-placement-closing-date-302359250.html